Wall Street brokerages predict that Adaptimmune Therapeutics PLC (NASDAQ:ADAP) will announce earnings of ($0.27) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Adaptimmune Therapeutics PLC’s earnings, with estimates ranging from ($0.28) to ($0.24). Adaptimmune Therapeutics PLC posted earnings of ($0.24) per share in the same quarter last year, which would suggest a negative year over year growth rate of 12.5%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 9th.

On average, analysts expect that Adaptimmune Therapeutics PLC will report full-year earnings of ($1.03) per share for the current financial year, with EPS estimates ranging from ($1.12) to ($0.92). For the next financial year, analysts anticipate that the business will post earnings of ($0.95) per share, with EPS estimates ranging from ($1.28) to ($0.54). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Adaptimmune Therapeutics PLC.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. The company had revenue of $3.52 million for the quarter, compared to analysts’ expectations of $5.43 million.

Several research firms have weighed in on ADAP. Leerink Swann reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a research report on Friday. BidaskClub raised Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. ValuEngine raised Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Zacks Investment Research downgraded Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Tuesday, June 6th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. Adaptimmune Therapeutics PLC currently has an average rating of “Hold” and an average target price of $12.08.

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded up 18.28% on Friday, reaching $8.93. 1,710,060 shares of the company’s stock traded hands. The firm’s 50 day moving average is $5.70 and its 200 day moving average is $5.18. The firm’s market capitalization is $835.12 million. Adaptimmune Therapeutics PLC has a 52 week low of $3.76 and a 52 week high of $8.95.

TRADEMARK VIOLATION NOTICE: “Adaptimmune Therapeutics PLC (ADAP) Expected to Post Earnings of -$0.27 Per Share” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/08/adaptimmune-therapeutics-plc-adap-expected-to-post-earnings-of-0-27-per-share.html.

Several institutional investors have recently made changes to their positions in ADAP. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth about $120,000. KCG Holdings Inc. acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth about $133,000. Monashee Investment Management LLC acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth about $138,000. OxFORD Asset Management LLP acquired a new position in shares of Adaptimmune Therapeutics PLC during the second quarter worth about $156,000. Finally, Paloma Partners Management Co acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth about $165,000. 68.01% of the stock is owned by institutional investors and hedge funds.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Get a free copy of the Zacks research report on Adaptimmune Therapeutics PLC (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.